Skip to content
Studies have shown that active fund managers routinely underperform the S&P500 index*
Home
Articles
WALL STREET X
Forecasts
Portfolios
Wall Street X
Articles
Forecasts
Portfolios
Search
Results for
{phrase}
(
{results_count}
of
{results_count_total}
)
Displaying
{results_count}
results of
{results_count_total}
Atrium Therapeutics, Inc. (NASDAQ: RNA)
RNA Stock Predictions and Ratings
WSX Rating:
STRONG SELL
WSX Forecast (1yr):
-7.50%
Analyst Rating:
BUY
Analyst Forecast (1yr):
400%
RNA Stock Analysis
RNA
PE Ratio:
RNA
PEG Ratio:
Not Available
RNA
Forward EPS Growth (12 month):
0.00%
RNA
PS Ratio:
11.2
RNA
PSG Ratio:
Not Available
RNA
Forward Revenue Growth (12 month):
0.00%
RNA Articles
No data was found